Back to search
FDAFDA · Food and drugs·Recall number D-0191-2024

Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, 1000 Tablets, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454. NDC: 45963-676-96

Published January 3, 2024 · Recall initiated: January 26, 2022

Summary

FDA records drug Class II recall D-0191-2024, published January 3, 2024 and initiated January 26, 2022. Recalling firm: CARDINAL HEALTHCARE; Status: Terminated; Reported quantity: 1 unit; Lot: Batch 2447J211. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
CARDINAL HEALTHCARE
Distributor
Nationwide USA
Lot
Batch 2447J211
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, 1000 Tablets, Rx Only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454. NDC: 45963-676-96 recalled?

Yes. FDA published recall D-0191-2024 on January 3, 2024. Reported hazard: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

What should I do if I have this product?

Voluntary: Firm initiated · Letter